ycopene nephrotoxicity prevention in cancer patients
Phase 2
- Conditions
- Drug induced nephropathy.Nephropathy induced by other drugs, medicaments and biological substances
- Registration Number
- IRCT2016050427745N1
- Lead Sponsor
- Vice chancellor for research, Shahrekord university of medical sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
The inclusion criteria were condidered to be suffering cancer without primary involvement or renal metastasis; being candidate for administration of 70-100 mg/m2 cisplatin; being 20-80 years old; Cr < 1.5; normal hearing; no underlying nephropathy; ; performance status of 0-2.
Exclusion criteria were death; allergy to lycopene; hearing loss; moderate to severe neuropathy; renal metastatic involvement.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method BUN. Timepoint: Before intervention, 7 & 21 days lft. Method of measurement: mg/dl - labratuary.;Cr. Timepoint: Before intervention, 7 & 21 days lft. Method of measurement: mg/dl - labratuary.;GFR. Timepoint: Before intervention, 7 & 21 days lft. Method of measurement: ml/min - calculation.
- Secondary Outcome Measures
Name Time Method